Characteristics of genetic variants in 134 patients with Acute myeloid leukemia.
10.3760/cma.j.cn511374-20221025-00718
- VernacularTitle:急性髓系白血病患者134例的基因变异特点
- Author:
Miao HE
1
;
Xiaochen ZHAO
;
Hongjuan TIAN
;
Shuting ZHANG
;
Fangqing ZHAO
;
Xi ZHANG
;
Tao WU
Author Information
1. Department of Hematology, the 940th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army, Lanzhou, Gansu 730050, China. wutaozhen@yeah.net.
- Publication Type:Journal Article
- MeSH:
Aged, 80 and over;
Female;
Humans;
Male;
Middle Aged;
Leukemia, Myeloid, Acute/genetics*;
Leukemia, Promyelocytic, Acute;
Nuclear Proteins;
Retrospective Studies;
Child;
Adolescent;
Young Adult;
Adult;
Aged;
East Asian People
- From:
Chinese Journal of Medical Genetics
2023;40(10):1222-1227
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To analyze the characteristics of genetic variants in 134 patients diagnosed with Acute myeloid leukemia (AML).
METHODS:Clinical data of the 134 patients with AML (non-acute promyelocytic leukemia) initially diagnosed at the 940th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army from June 2017 to June 2022 were retrospectively analyzed. Potential variants of AML-related genes were detected by next-generation sequencing, and the frequency of variants was analyzed by using SPSS v26.0 software, and likelihood ratio χ2 test and Fisher exact test were used for data analysis.
RESULTS:The patients had included 72 males and 62 females, with a gender ratio of 1.7 : 1 and a median age of 51 years (9 ~ 86 years old). One hundred twenty patients (76.1%) had harbored at least one genetic variant, including 26 (19.4%) having a single variant, 27 (20.1%) having two variants, and 49 (36.6%) having >= 3 variants. 32 (23.9%) had no detectable variants. Genetic variants detected in over 10% of the 134 patients had included NPM1 (n = 24, 17.91%), FLT3-ITD (n = 21, 15.67%), DNMT3A (n = 20, 14.93%), CEBPA (single variant; n = 14, 10.45%), TET2 (n = 14, 10.45%), and NRAS (n = 14, 10.45%). The patients were also divided into low risk, intermediate risk and high risk groups based on their chromosomal karyotypes. The mutational rates for genes in different groups have varied, with 19 patients from the low risk group harboring variants of NRAS (n = 4, 21.05%), KRAS (n = 4, 21.05%), and KIT (n = 2, 10.53%); and 96 patients from the intermediate risk group harboring variants of NPM1 (n = 24, 25.00%), FLT3-ITD (n = 20, 20.83%), DNMT3A (n = 18, 18.75%), CEBPA (n = 12, 12.50%), and TET2 genes (n = 12, 12.50%). The mutational frequencies for the 19 patients from the high risk group were ASXL1 (n = 7, 21.05%), NRAS (n = 3, 15.97%), TP53 (n = 3, 15.79%), and EZH2 (n = 2, 10.53%). A significant difference was found in the frequencies of KIT, NPM1, FLT3-ITD, DNMT3A, and ASXL1 gene variants among the low-risk, medium-risk, and high-risk groups.
CONCLUSION:AML patients have a high frequency for genetic variants, with 76.1% harboring at least one variant. The frequency of genetic variants have varied among patients with different chromosomal karyotypes, and there are apparent dominant variants. KIT, NPM1, FLT3-ITD, DNMT3A, and ASXL1 may be used as prognostic factors for evaluating their prognosis.
